Business Context and Reporting Period
Autolus Therapeutics Plc, a foreign private issuer, filed Form 6-K on December 20, 2018, to report a change in its fiscal year end. The company is headquartered in London, United Kingdom.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance change rather than financial performance.
Material Changes
- Fiscal Year Change: On December 19, 2018, the Board of Directors approved changing the fiscal year end from September 30 to December 31.
- Transition Period: The company will file a transition report on Form 20-F covering the period from October 1, 2018, to December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, risk factors, contingencies, or unusual items beyond the administrative change to the fiscal calendar.
Investor Verification Checklist
- Verify the upcoming Form 20-F transition report for the period October 1, 2018, to December 31, 2018.
- Confirm the new fiscal year end date of December 31 for future reporting cycles.
- Review the company's previous fiscal year (ending September 30) for the most recent complete financial data.